Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis.

Purpose: To report on two patients with refractory uveitis treated with tocilizumab; a new humanized monoclonal antibody against the interleukin-6 receptor (IL-6R).

Design: Retrospective interventional case series.

Methods: Both patients received a monthly infusion of tocilizumab 8 mg/kg; associated with corticosteroids. Outcome measures were visual acuity and central retinal thickness evaluated with optical coherence tomography.

Results: An improvement in visual acuity and a decrease in macular edema were observed in these two patients.

Conclusions: Tocilizumab seems to be a promising treatment in refractory uveitis. A prospective study is needed to evaluate the role of this new agent in the management of refractory uveitis.